申请人:Schering Aktiengesellschaft
公开号:US04364950A1
公开(公告)日:1982-12-21
5-cyano-prostacyclins of the formula ##STR1## wherein R.sub.1 is OR.sub.2 or NHR.sub.3 ; R.sub.2 and R.sub.3 each independently is (a) H, (b) C.sub.1-10 -alkyl, (c) C.sub.1-10 -alkyl substituted by halo, C.sub.1-4 -alkoxy or phenyl, 1-naphthyl or 2-naphthyl, each optionally substituted as defined below, (d) C.sub.4-10 -cycloalkyl, (e) C.sub.4-10 -cycloalkyl substituted by C.sub.1-4 -alkyl, (f) phenyl, 1-naphthyl or 2-naphthyl, (g) phenyl, 1-naphthyl or 2-naphthyl substituted by 1-3 halogen atoms, phenyl, 1-3 alkyl groups of 1-4 C atoms each, or a chloromethyl-, fluoromethyl-, trifluoromethyl-, carboxyl-, hydroxy- or alkoxy-group of 1-4 C atoms, or (h) an aromatic, 5- or 6-membered heterocyclic ring containing one hetero atom which is O, N or S, the remaining atoms being carbon; R.sub.3 also possibly being an acyl group of a C.sub.1-15 -hydrocarbon carboxylic or sulfonic acid; B is straight chain or branched alkylene of 2-10 C atoms; W is hydroxymethylene or ##STR2## wherein the OH group may be in the alpha or beta position, and is optionally modified by replacement of the H atom of the OH with an ether or acyl group which is conventional for such replacements in prostaglandins and which is readily cleavable at physiological pH's; R.sub.4 is hydroxy, optionally modified as described for W above; R.sub.5, R.sub.6, R.sub.7 and R.sub.8 each independently is hydrogen, alkyl of 1-5 C atoms or methoxy; and R.sub.9 is alkyl of 1-5 C atoms or for compounds wherein R.sub.2 is H, the salts thereof with physiologically compatible bases have valuable pharmacalogical properties, e.g., hypertonic and bronchodilatory activities.
公式为##
STR1##的5-
氰基
前列环素,其中R.sub.1是OR.sub.2或NHR.sub.3; R.sub.2和R.sub.3各自独立地是(a) H,(b) C.sub.1-10-烷基,(c) C.sub.1-10-烷基,被卤素,C.sub.1-4-烷
氧基或
苯基取代,1-
萘基或2-
萘基,每个都可以选择如下定义的取代基,(d) C.sub.4-10-
环烷基,(e) C.sub.4-10-
环烷基,被C.sub.1-4-烷基取代,(f)
苯基,1-
萘基或2-
萘基,(g)
苯基,1-
萘基或2-
萘基,被1-3个卤素原子,
苯基,1-4个C原子的1-3个烷基或
氯甲基,
氟甲基,三
氟甲基,羧基,羟基或1-4个C原子的烷
氧基取代,或(h)芳香,含有一个杂原子的5-或6-成员杂环,该杂原子为O,N或S,其余原子为
碳; R.sub.3也可能是C.sub.1-15-烃基
羧酸或
磺酸的酰基; B是直链或支链烷基,具有2-10个C原子; W是
羟甲基或##
STR2##其中OH基可以在α或β位置,且可选择通过将OH的H原子替换为在
前列腺素中常用的醚或酰基来修改,该醚或酰基在生理pH下容易被裂解; R.sub.4是羟基,可根据上述W进行修改; R.sub.5,R.sub.6,R.sub.7和R.sub.8各自独立地是
氢,1-5个C原子的烷基或甲
氧基; R.sub.9是1-5个C原子的烷基,或者在R.sub.2为H的化合物中,其与生理兼容的碱盐具有有价值的药理学特性,例如高渗和支气管扩张活性。